Research advances in the biomarkers of brain damage in preterm infants.
- Author:
Mei YAO
1
;
Shan-Shan MAO
Author Information
1. Department of Neurology, Zhejiang University School of Medicine, Hangzhou 310052, China. 6307003@zju.edu.cn.
- Publication Type:Journal Article
- MeSH:
Biomarkers;
Brain;
Brain Injuries;
Female;
Humans;
Infant;
Infant, Newborn;
Infant, Premature;
Pregnancy;
S100 Calcium Binding Protein beta Subunit
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(11):1138-1143
- CountryChina
- Language:Chinese
-
Abstract:
While the survival rate of preterm infants has continually increased with the development of perinatal and neonatal monitoring techniques, the incidence of brain injury in preterm infants has been increasing, resulting in varying degrees of cognitive impairment and movement disorders. Measuring the biomarkers of brain damage is an important means to diagnose brain injury. The biomarkers can be divided into neuroglial damage markers, neuronal damage markers and other markers according to the features of injured cells. The biomarkers widely used in clinical practice include S100B protein, myelin basic protein and neuron-specific enolase. Recent studies have newly discovered a collection of markers that can suggest potential brain injury in preterm infants, such as glial fibrillary acidic protein, neurofilament light chain protein, α-II spectrin breakdown products, chemokines, melatonin and urinary metabolomics. These biomarkers can contribute to the early diagnosis and treatment of preterm brain injury, essential for improving neural development and prognosis. This article reviews the latest research advances in the biomarkers of preterm brain injury, in order to provide evidence for the early diagnosis and treatment of this condition.
